What is your approach to adjuvant therapy for an R0, ALK+ resected lung adenocarcinoma with N2 disease?  

This is a timely question for me as well as the community. For me as I have just had my first patient presenting with ALK-positive 3A cancer PREOPERATIVELY. For the community as there was a recent presentation at ESMO of the ALINA trial. In the ALINA trial, patients with ALK-positive NSCLC were rand...